Analysts Set Humacyte, Inc. (NASDAQ:HUMA) PT at $13.71

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) has been assigned an average recommendation of "Buy" from the eight analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $13.71.

Several analysts have recently weighed in on HUMA shares. D. Boral Capital restated a "buy" rating and set a $25.00 price target on shares of Humacyte in a report on Monday. Benchmark lifted their price objective on Humacyte from $15.00 to $17.00 and gave the stock a "buy" rating in a research note on Monday, December 23rd. Cantor Fitzgerald reissued an "overweight" rating and issued a $13.00 price target on shares of Humacyte in a research note on Friday, September 20th. HC Wainwright reaffirmed a "buy" rating and set a $15.00 target price (up from $12.00) on shares of Humacyte in a research report on Friday, December 20th. Finally, TD Cowen reaffirmed a "buy" rating and set a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th.

Insider Buying and Selling

In other Humacyte news, Director Brady W. Dougan sold 427,459 shares of the company's stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the transaction, the director now owns 1,992,253 shares in the company, valued at $8,646,378.02. This represents a 17.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Laura E. Niklason sold 811,172 shares of the company's stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.44, for a total value of $3,601,603.68. Following the completion of the transaction, the chief executive officer now owns 2,419,712 shares of the company's stock, valued at $10,743,521.28. This trade represents a 25.11 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,500,000 shares of company stock worth $6,606,799. 11.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. State Street Corp increased its holdings in Humacyte by 66.1% during the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company's stock worth $25,917,000 after acquiring an additional 1,895,529 shares during the period. Millennium Management LLC increased its holdings in shares of Humacyte by 504.3% in the second quarter. Millennium Management LLC now owns 1,599,307 shares of the company's stock worth $7,677,000 after purchasing an additional 1,334,641 shares during the period. Renaissance Technologies LLC grew its position in Humacyte by 693.0% during the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company's stock worth $2,881,000 after buying an additional 524,600 shares in the last quarter. Marshall Wace LLP increased its stake in Humacyte by 3,301.5% in the 2nd quarter. Marshall Wace LLP now owns 463,662 shares of the company's stock worth $2,226,000 after acquiring an additional 450,031 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C purchased a new stake in shares of Humacyte in the 2nd quarter valued at about $1,550,000. Hedge funds and other institutional investors own 44.71% of the company's stock.

Humacyte Trading Down 2.2 %

Humacyte stock traded down $0.10 during midday trading on Monday, reaching $4.48. The company's stock had a trading volume of 1,924,718 shares, compared to its average volume of 3,364,885. Humacyte has a 52 week low of $2.48 and a 52 week high of $9.97. The business has a 50-day moving average price of $4.60 and a 200-day moving average price of $5.66. The stock has a market cap of $563.85 million, a PE ratio of -3.34 and a beta of 1.32.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.